Cross-trial analysis of immunological and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax®) in colorectal, renal and prostate cancer patients

被引：0
|
作者：
Harrop, R. [1 ]
Shingler, W. H. [1 ]
Drury, N. [1 ]
Goonewardena, M. [1 ]
de Belin, J. [1 ]
Naylor, S. [1 ]
Treasure, P. [1 ]
机构：
[1] Peter Treasure Stat Serv Ltd, NA, Cambridge, England
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72535-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：188 / 188
页数：1
相关论文
共 50 条
  • [41] Clinical results of a Phase I/II trial of adjuvant therapeutic vaccination in high risk resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and survivin
    Tryggestad, Anne Merete Aa.
    Axcrona, Karol
    Bigalke, Iris
    Inderberg-Suso, Else M.
    Skorstad, Gjertrud
    Axcrona, Ulrika
    Aamdal, Steinar
    Gaudernack, Gustav
    Schendel, Dolores
    Lilleby, Wolfgang
    Dueland, Svein
    Kvalheim, Gunnar
    CANCER RESEARCH, 2016, 76
  • [42] Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials
    Mayanagi, Shuhei
    Oba, Koji
    Aoyama, Toru
    Tanaka, Kenji
    Kanda, Mitsuro
    Honda, Michitaka
    Maeda, Hiromichi
    Kashiwabara, Kosuke
    Muto, Masaru
    Sakamoto, Junichi
    Yamagishi, Hisakazu
    Yoshikawa, Takaki
    ANTICANCER RESEARCH, 2023, 43 (07) : 3089 - 3095
  • [43] EFFICACY AND SAFETY OF MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) AFTER COMPLETING AT LEAST 4 CYCLES OF PEMETREXED PLUS CISPLATIN INDUCTION TREATMENT: A CROSS-TRIAL ANALYSIS OF TWO PHASE III TRIALS
    Scagliotti, Giorgio V.
    Gridelli, Cesare
    De Marinis, Filippo
    Thomas, Michael
    Dediu, Mircea
    Pujol, Jean-Lois
    Manegold, Christian
    San Antonio, Belen
    Peterson, Patrick M.
    John, William J.
    Chouaki, Nadia
    Visseren-Grul, Carla
    Paz-Ares, Luis G.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S877 - S878
  • [44] Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T 161 Tb]Tb-PSMA-I&T
    Buteau, James P.
    Kostos, Louise
    Alipour, Ramin
    Jackson, Price
    McInstosh, Lachlan
    Emmerson, Brittany
    Haskali, Mohammad B.
    Xie, Jing
    Medhurst, Elizabeth
    Ravi, Rajeev
    Gonzalez, Brian D.
    Fettke, Heidi
    Blyth, Benjamin
    Furic, Luc
    Owen, Katie
    Sandhu, Shahneen
    Murphy, Declan G.
    Azad, Arun A.
    Hofman, Michael S.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (08) : 1231 - 1238
  • [45] Renal safety of linagliptin in elderly patients with type 2 diabetes mellitus (T2DM): analysis of pooled patient data from 7 phase 3 clinical trials
    Patel, S.
    Schernthaner, G.
    Barnett, A. H.
    Hehnke, U.
    Woerle, H. J.
    von Eynatten, M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2014, 62 : S182 - S182
  • [46] Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB
    Ajani, Jaffer A.
    Udrea, Anghel Adrian
    Sarosiek, Tomasz
    Schenker, Michael
    Morgan, Carys
    Pikiel, Joanna
    Joseph, Mano
    Salek, Tomas
    Tournigand, Christophe
    Ferry, David Raymond
    Zhang, Yawei
    Long, Amanda
    Kuo, Wen-Ling
    Gao, Ling
    Russo, Francesca
    Mansoor, Wasat
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [47] Early assessment of efficacy of ixabepilone (IXA) by analysis of the rate of tumor growth and decay using data from phase II and phase III clinical trials in metastatic breast cancer (MBC) patients (Pts).
    Amiri-Kordestani, L.
    Jawed, I.
    Wilkerson, J.
    Stein, W. D.
    Fojo, A. T.
    Swain, S. M.
    Bates, S. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.
    Tuthill, Mark
    Cappuccini, Federica
    Bryant, Richard John
    Poulton, Ian
    Pollock, Emily
    Carter, Lucy
    Verrill, Clare
    Meier, Armin
    Schmidt, Gunter
    Catto, James W. F.
    Evans, Tom
    Gillessen, Silke
    Protheroe, Andrew
    Hamdy, Freddie
    Hill, Adrian V. S.
    Redchenko, Irina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Phase II study of the DNA methyltransferase I (DNMT1) inhibitor MG98 in patients (Pts) with Renal Cell Carcinoma (RCC). A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)
    Winquist, E
    Knox, J
    Ayoub, JP
    Wood, L
    Wainman, N
    Pearce, L
    Shah, A
    Eisenhauer, E
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S141 - S141
  • [50] Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
    Modi, S.
    Glass, B.
    Prakash, A.
    Taylor-Weiner, A.
    Elliott, H.
    Wapinski, I.
    Sugihara, M.
    Saito, K.
    Kerner, J. Kaplan
    Phillips, R.
    Shibutani, T.
    Honda, K.
    Khosla, A.
    Beck, A. H.
    Cogswell, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S355 - S356
12345